{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:04:58Z","timestamp":1791777898008,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This prospective phase I\/II trial assessed feasibility and efficacy of dose-escalated definitive chemoradiation after induction chemotherapy in locally advanced esophageal cancer. Primary study endpoint was loco-regional progression-free survival at 1\u00a0year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible patients received 2 cycles of induction chemotherapy with irinotecan, folinic acid and 5-fluorouracil weekly and cisplatin every 2\u00a0weeks (weeks 1\u20136, 8\u201313) followed by concurrent chemoradiation with cisplatin and irinotecan (weeks 14, 15, 17, 18, 20). Radiotherapy dose escalation was performed in three steps (60\u00a0Gy, 66\u00a0Gy, 72\u00a0Gy) using conventional fractionation, planning target volumes were delineated with the aid of 18F-FDG-PET\/CT scans. During follow-up, endoscopic examinations were performed at regular intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 09\/2006 and 02\/2010, 17 patients were enrolled (male\/female:13\/4, median age: 59 [range 48\u201366] years, stage uT3N0\/T3N1\/T4N1: 4\/12\/1). One patient progressed during induction chemotherapy and underwent surgery. Of 16 patients treated with definitive chemoradiotherapy, 9 (56%) achieved complete response after completion of chemoradiation. One-, 2-, 3- and 5-year overall survival rates (OS) were 77% [95%CI: 59\u2013100], 53% [34\u201383], 41% [23\u201373], and 29% [14\u201361], respectively. Loco-regional progression-free survival at 1, 3, and 5\u00a0years was 59% [40\u201388], 35% [19\u201367], and 29% [14\u201361], corresponding cumulative incidences of loco-regional progressions were 18% [4\u201339%], 35% [14\u201358%], and 41% [17\u201364%]. No treatment related deaths occurred. Grade 3 toxicities during induction therapy were: neutropenia (41%), diarrhoea (41%), during combined treatment: neutropenia (62%) and thrombocytopenia (25%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dose-escalated radiotherapy and concurrent cisplatin\/irinotecan after cisplatin\/irinotecan\/5FU induction chemotherapy was tolerable. The hypothesized phase II one-year loco-regional progression free survival rate of 74% was not achieved. Long-term survival compares well with other studies on definitive radiotherapy using irinotecan and cisplatin but is not better than recent trials using conventionally fractionated radiotherapy ad 50\u00a0Gy with concurrent paclitaxel or 5FU and platinum compound.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> The present trial was registered as a phase I\/II trial at the EudraCT database: Nr. 2005-006097-10 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-006097-10\/DE\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-006097-10\/DE<\/jats:ext-link>) and authorized to proceed on 2006-09-25.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01788-4","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:07:04Z","timestamp":1616526424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dose-escalated radiotherapy with PET\/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3\/T4) squamous cell cancer of the esophagus: mature results of a phase I\/II trial"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-9318","authenticated-orcid":false,"given":"C.","family":"P\u00f6ttgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Abu Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Trarbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-H.","family":"J\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"1788_CR1","unstructured":"World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: oesophagus cancer fact sheet.2018. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/6-Oesophagus-fact-sheet.pdf. Accessed 23 Nov 2020."},{"key":"1788_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301). Radiation Therapy Oncology Group. JAMA. 1999;281:1623\u20137.","journal-title":"JAMA"},{"key":"1788_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JCO.1997.15.1.277","volume":"15","author":"M al-Sarraf","year":"1997","unstructured":"al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277\u201384.","journal-title":"J Clin Oncol."},{"key":"1788_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, Bouch\u00e9 O, Gourgou-Bourgade S, Douillard JY, et al. F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15:305\u201314.","journal-title":"Lancet Oncol."},{"key":"1788_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bjc.2017.21","volume":"116","author":"T Crosby","year":"2017","unstructured":"Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, et al. Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy +\/- cetuximab in oesophageal cancer. Br J Cancer. 2017;116:709\u201316.","journal-title":"Br J Cancer"},{"key":"1788_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","volume":"3","author":"M Suntharalingam","year":"2017","unstructured":"Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017;3:1520\u20138.","journal-title":"JAMA Oncol"},{"key":"1788_CR7","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310\u20137.","journal-title":"J Clin Oncol"},{"key":"1788_CR8","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","volume":"25","author":"L Bedenne","year":"2007","unstructured":"Bedenne L, Michel P, Bouch\u00e9 O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160\u20138.","journal-title":"J Clin Oncol"},{"key":"1788_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167\u201374.","journal-title":"J Clin Oncol"},{"key":"1788_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593\u20138.","journal-title":"N Engl J Med."},{"issue":"Suppl 4","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1200\/JCO.2020.38.4_suppl.281","volume":"38","author":"MCCM Hulshof","year":"2020","unstructured":"Hulshof MCCM, Geijsen D, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol. 2020;38(Suppl 4):281.","journal-title":"J Clin Oncol."},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ctrv.2011.10.005","volume":"38","author":"C P\u00f6ttgen","year":"2012","unstructured":"P\u00f6ttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer\u2014a meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38:599\u2013604.","journal-title":"Cancer Treat Rev"},{"key":"1788_CR13","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2003.02.147","volume":"21","author":"DH Ilson","year":"2003","unstructured":"Ilson DH, Bains M, Kelsen DP, Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003;21:2926\u201332.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/sj.bjc.6603328","volume":"95","author":"P Michel","year":"2006","unstructured":"Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95(6):705\u20139.","journal-title":"Br J Cancer"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ijrobp.2008.12.087","volume":"75","author":"F Rivera","year":"2009","unstructured":"Rivera F, Gal\u00e1n M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, et al. Spanish Cooperative Group for Digestive Tumor Therapy. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009;75:1430\u20136.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1788_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2015.12.009","volume":"94","author":"LR Kleinberg","year":"2016","unstructured":"Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB 3rd. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network randomized phase 2 trial of neoadjuvant preoperative paclitaxel\/cisplatin\/radiation therapy (RT) or irinotecan\/cisplatin\/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design. Int J Radiat Oncol Biol Phys. 2016;94:738\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR17","volume-title":"Base SAS\u00ae 9.4 procedures guide: statistical procedures","author":"SAS Institute Inc","year":"2016","unstructured":"SAS Institute Inc. Base SAS\u00ae 9.4 procedures guide: statistical procedures. 6th ed. SAS Institute Inc.; 2016.","edition":"6"},{"key":"1788_CR18","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"1788_CR19","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45:1388\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"1788_CR20","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/cncr.26591","volume":"118","author":"DH Ilson","year":"2012","unstructured":"Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2012;118:2820\u20137.","journal-title":"Cancer"},{"key":"1788_CR21","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1002\/cncr.25349","volume":"116","author":"JJ Knox","year":"2010","unstructured":"Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 2010;116:4023\u201332.","journal-title":"Cancer"},{"key":"1788_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1634\/theoncologist.2012-0208","volume":"18","author":"MS Lee","year":"2013","unstructured":"Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013;18:281\u20137.","journal-title":"Oncologist"},{"key":"1788_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/JTO.0b013e31824c7bed","volume":"7","author":"MB Tomblyn","year":"2012","unstructured":"Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, et al. SWOG GI Committee. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol. 2012;7:906\u201312.","journal-title":"J Thorac Oncol."},{"key":"1788_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/COC.0b013e3181aaca26","volume":"33","author":"BN Ruppert","year":"2010","unstructured":"Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, et al. Cisplatin\/Irinotecan versus carboplatin\/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010;33:346\u201352.","journal-title":"Am J Clin Oncol"},{"key":"1788_CR25","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1200\/JCO.2007.12.3471","volume":"25","author":"G Crehange","year":"2007","unstructured":"Crehange G, Maingon P, Peignaux K, N\u2019guyen TD, Mirabel X, Marchal C, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol. 2007;25:4895\u2013901.","journal-title":"J Clin Oncol."},{"key":"1788_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.radonc.2006.02.014","volume":"78","author":"T Leong","year":"2006","unstructured":"Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol. 2006;78:254\u201361.","journal-title":"Radiother Oncol"},{"key":"1788_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.radonc.2010.04.024","volume":"97","author":"CT Muijs","year":"2010","unstructured":"Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT, Langendijk JA. A systematic review on the role of FDG-PET\/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol. 2010;97:165\u201371.","journal-title":"Radiother Oncol"},{"key":"1788_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.critrevonc.2016.08.015","volume":"107","author":"J Lu","year":"2016","unstructured":"Lu J, Sun XD, Yang X, Tang XY, Qin Q, Zhu HC, et al. Impact of PET\/CT on radiation treatment in patients with esophageal cancer: a systematic review. Crit Rev Oncol Hematol. 2016;107:128\u201337.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1788_CR29","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s12094-018-1879-3","volume":"20","author":"E Jimenez-Jimenez","year":"2018","unstructured":"Jimenez-Jimenez E, Mateos P, Aymar N, Roncero R, Ortiz I, Gimenez M, Pardo J, Salinas J, Sabater S. Radiotherapy volume delineation using 18F-FDG-PET\/CT modifies gross node volume in patients with oesophageal cancer. Clin Transl Oncol. 2018;20(11):1460\u20136.","journal-title":"Clin Transl Oncol"},{"key":"1788_CR30","doi-asserted-by":"publisher","first-page":"22711","DOI":"10.18632\/oncotarget.8050","volume":"7","author":"J Chen","year":"2016","unstructured":"Chen J, Guo H, Zhai T, Chang D, Chen Z, Huang R, et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget. 2016;7:22711\u20139.","journal-title":"Oncotarget"},{"key":"1788_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jtho.2016.10.013","volume":"12","author":"JW Welsh","year":"2017","unstructured":"Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I\/II trial. J Thorac Oncol. 2017;12:375\u201382.","journal-title":"J Thorac Oncol"},{"key":"1788_CR32","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/jamaoncol.2019.2809","volume":"5","author":"D Chen","year":"2019","unstructured":"Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, et al. Results of a phase 1\/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer. JAMA Oncol. 2019;5:1597\u2013604.","journal-title":"JAMA Oncol"},{"key":"1788_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13014-019-1225-0","volume":"14","author":"S Gwynne","year":"2019","unstructured":"Gwynne S, Higgins E, Poon King A, Radhakrishna G, Wills L, Mukherjee S, et al. Driving developments in UK oesophageal radiotherapy through the SCOPE trials. Radiat Oncol. 2019;14:26.","journal-title":"Radiat Oncol"},{"key":"1788_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ijrobp.2014.06.028","volume":"90","author":"S Warren","year":"2014","unstructured":"Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR35","doi-asserted-by":"publisher","unstructured":"The SCOPE 2 Trial: Study of chemoradiotherapy in oesophageal cancer including PET response and dose escalation. ISRCTN97125464. https:\/\/doi.org\/10.1186\/ISRCTN97125464. Accessed 07\/02\/2021.","DOI":"10.1186\/ISRCTN97125464"},{"key":"1788_CR36","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/bjc.2015.416","volume":"113","author":"A Chhabra","year":"2015","unstructured":"Chhabra A, Ong LT, Kuk D, Ku G, Ilson D, Janjigian YY, et al. Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. Br J Cancer. 2015;113:1658\u201365.","journal-title":"Br J Cancer"},{"key":"1788_CR37","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ijc.32897","volume":"147","author":"S Zschaeck","year":"2020","unstructured":"Zschaeck S, Li Y, B\u00fctof R, Lili C, Hua W, Troost ECG, et al. Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. Int J Cancer. 2020;147:1427\u201336.","journal-title":"Int J Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-021-01788-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:12:18Z","timestamp":1616526738000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01788-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01788-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics committee of the Medical Faculty of University of Duisburg-Essen (Reference Number 05-2682).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C. P\u00f6ttgen: honoraria from Roche, Boehringer Ingelheim, AstraZeneca. M. Stahl: honoraria from Roche, Pfizer, Ortho Biotech. T. Gauler: honoraria from Roche, AstraZeneca, Lilly Germany. S. Kasper: honoraria from Amgen, Bayer, BMS, Celgene, Lilly, Merck, MSD, Roche and Sanofi. T Trarbach: honoraria from Schering-Plough, Novartis; Research funding: Amgen, Eli Lilly, Saladex. E. Gkika, J. Abu Jawad, K. Herrmann, N. Lehmann, K.-H. J\u00f6ckel, H. Lax, and M. Stuschke declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}